Will Sanofi's Lantus Survive Cancer Scare? Studies Suggest a Worrisome Link

But the data also suggest a higher cancer risk could be due to "patient characteristics," and not Lantus itself.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet